Leslie Meltzer

Chief Research and Development, Apellis Pharmaceuticals, Inc.

Companies

Apellis Pharmaceuticals, Inc.Chief Research and Development Sep 2, 2025 to now¹

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Apellis Pharmaceuticals, Inc.0 shares²May 14, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

May 14, 2026Returned to company 45,220 shares of Apellis Pharmaceuticals, Inc.²
May 14, 2026Returned to company 61,804 shares of Apellis Pharmaceuticals, Inc.²
May 14, 2026Returned to company 45,220 shares of Apellis Pharmaceuticals, Inc.²
May 14, 2026Granted 45,220 shares of Apellis Pharmaceuticals, Inc.²
May 14, 2026Returned to company 22,610 shares of Apellis Pharmaceuticals, Inc.²
May 14, 2026Granted 22,610 shares of Apellis Pharmaceuticals, Inc.²
May 14, 2026U 107,024 shares of Apellis Pharmaceuticals, Inc.²
Jan 28, 2026Granted 45,220 shares of Apellis Pharmaceuticals, Inc.³
Aug 26, 2025Granted 61,804 shares of Apellis Pharmaceuticals, Inc.⁴

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARApellis Pharmaceuticals, Inc., Chief Research and Development
2
SEC EDGARApellis Pharmaceuticals, Inc. shares after the filing of May 14, 2026
3
SEC EDGARForm 4 filed Jan 30, 2026
4
SEC EDGARForm 4 filed Sep 2, 2025